Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver? (Q47605309)

4 February 2018

editorial

0 references

title

Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver? (English)

1 reference

4 February 2018

1

Marcin Kortylewski

1 reference

4 February 2018

author name string

Sergey Nechaev

series ordinal

2

1 reference

4 February 2018

publication date

1 March 2014

1 reference

4 February 2018

published in

Therapeutic delivery

1 reference

4 February 2018

volume

5

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

page(s)

239-242

1 reference

4 February 2018

Transcription factors as targets for cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Antitumorigenic potential of STAT3 alternative splicing modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Progress toward in vivo use of siRNAs-II

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

RNAi joins the "Singles Club"

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Intracellular delivery of RNA-based therapeutics using aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Current progress of RNA aptamer-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.13.152

21 January 2018

Identifiers

DOI

10.4155/TDE.13.152

1 reference

4 February 2018

PubMed ID

24592948

1 reference

4 February 2018